Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333282 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6294388 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371368 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371871 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371272 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2380100 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2372025 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2370725 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371133 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2370650 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013093928-A1 | AN IMPROVED PROCESS FOR PREPARING 2-OXINDOLES OF FORMULA I, A KEY RAW MATERIAL FOR MAKING PHARMACEUTICAL DRUGS AND INTERMEDIATES THEREOF | ARCH PHARMALABS LIMITED (IN) | 2013-06-27 | — | — | WO | disclosed |
| US-7148371-B2 | Method for producing lysine derivative | AJINOMOTO CO., INC. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-7012152-B2 | Method for producing lysine derivative | AJINOMOTO CO., INC. (JP) | 2006-03-14 | — | — | US | disclosed |
| US-20060004103-A1 | Method for producing lysine derivative | AJINOMOTO CO., INC. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-6664412-B2 | Protecting amino group or amino group and carboxyl group of optically active 2-amino-6-methyl-6-nitroheptanoic acid with protecting group, reducing nitro group to synthesize 6,6-dimethyllysine and reacting this with acetic acid | AJINOMOTO CO., INC. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-6469181-B1 | PREPARING 2-OXINDOLES AND N-HYROXY-2- OXINDOLES VIA REDUCTION OF 2-NITROARYLMALONATE DIESTERS WITHOUT ISOLATION OF INTERMEDIATES | CATALYTICA, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-0809631-A4 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA INC (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0809631-A1 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA, INC. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996023770-A1 | PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES | CATALYTICA, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004103-A1 | Method for producing lysine derivative | JMJD6, SIRT6, KDM6A | GPR84 3479/4885FFAR1 2172/4885MAPT 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.